Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Evolving therapeutic goals in ulcerative colitis: towards disease clearance

Nature Reviews Gastroenterology & Hepatology volume 17, pages 1–2 (2020)Cite this article

Subjects

In ulcerative colitis, treating beyond endoscopic healing has shown a reduction of relapse and hospitalization, pushing for histological remission to be embraced in clinical practice and clinical trials. Here, we propose the concept of disease clearance (symptomatic, endoscopic and histological remission) as the ultimate goal in the treatment of ulcerative colitis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Disease clearance in ulcerative colitis.

References

  1. Ungaro, R. et al. A Treat-to-target update in ulcerative colitis: a systematic review. Am. J. Gastroenterol. 114, 874–883 (2019).

    Article  Google Scholar 

  2. Peyrin–Biroulet, L., Bressenot, A. & Kampman, W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin. Gastroenterol. Hepatol. 12, 929–934 (2014).

    Article  Google Scholar 

  3. Strober, B. E. et al. Clinical goals and barriers to effective psoriasis care. Dermatol. Ther. 9, 5–18 (2019).

    Article  Google Scholar 

  4. Boni, E. Elewski et al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. J. Dermatolog Treat. 28, 492–499 (2017).

    Article  Google Scholar 

  5. Shelton, S. K. et al. Ixekizumab: a review of its use for the management of moderate to severe plaque psoriasis. Ann. Pharmacother. 53, 276–284 (2019).

    Article  CAS  Google Scholar 

  6. Peyrin-Biroulet, L. et al. Clinical remission as defined by the Mayo Score: do we deceive ourselves? Inflamm. Bowel Dis. 21, 2–3 (2015).

    Article  Google Scholar 

  7. Ma, C. et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment. Pharmacol. Ther. 50, 5–23 (2019).

    Article  CAS  Google Scholar 

  8. Fernandez-Blanco, J. I. et al. Adalimumab for induction of histological remission in moderately to severely active ulcerative colitis. Digestive Diseases Sci. 63, 731–737 (2018).

    Article  CAS  Google Scholar 

  9. Arijs, I. et al. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut 67, 43–52 (2018).

    Article  CAS  Google Scholar 

  10. Schoepfer, A. M. et al. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J. Crohns Colitis 6, 412–418 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy

    Silvio Danese & Giulia Roda

  2. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

    Silvio Danese

  3. Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France

    Laurent Peyrin-Biroulet

Authors
  1. Silvio Danese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulia Roda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurent Peyrin-Biroulet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvio Danese.

Ethics declarations

Competing interests

S.D. has served as a speaker, consultant, and advisory board member for Schering-Plough, AbbVie, Actelion, Alphawasserman, AstraZeneca, Cellerix, Cosmo Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson and Johnson, Millenium Takeda, MSD, Nikkiso Europe GmbH, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, UCB Pharma and Vifor. L.P.-B. reports personal fees from AbbVie, Allergan, Alma, Amgen, Arena, Biogen, Boerhinger Ingelheim, Celgene, Celltrion, Enterome, Ferring, Genentech, Gilead, Hikma, Index Pharmaceuticals, Janssen, MSD, Nestle, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Takeda and Tillots; grants from Abbvie, MSD and Takeda; and stock options from CTMA. G.R. declares no competing interests.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Danese, S., Roda, G. & Peyrin-Biroulet, L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol 17, 1–2 (2020). https://doi.org/10.1038/s41575-019-0211-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-019-0211-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing